TY - JOUR
T1 - Patient similarity and other artificial intelligence machine learning algorithms in clinical decision aid for shared decision-making in the Prevention of Cardiovascular Toxicity (PACT)
T2 - a feasibility trial design
AU - for the Cardio-Oncology Artificial Intelligence Informatics and Precision Equity (CAIPE) Research Team Investigators
AU - Brown, Sherry Ann
AU - Chung, Brian Y.
AU - Doshi, Krishna
AU - Hamid, Abdulaziz
AU - Pederson, Erin
AU - Maddula, Ragasnehith
AU - Hanna, Allen
AU - Choudhuri, Indrajit
AU - Sparapani, Rodney
AU - Bagheri Mohamadi Pour, Mehri
AU - Zhang, Jun
AU - Kothari, Anai N.
AU - Collier, Patrick
AU - Caraballo, Pedro
AU - Noseworthy, Peter
AU - Arruda-Olson, Adelaide
N1 - Funding Information:
Research was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number T35HL072483, as well as the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) under award numbers KL2TR001438 and UL1TR001436. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Background: The many improvements in cancer therapies have led to an increased number of survivors, which comes with a greater risk of consequent/subsequent cardiovascular disease. Identifying effective management strategies that can mitigate this risk of cardiovascular complications is vital. Therefore, developing computer-driven and personalized clinical decision aid interventions that can provide early detection of patients at risk, stratify that risk, and recommend specific cardio-oncology management guidelines and expert consensus recommendations is critically important. Objectives: To assess the feasibility, acceptability, and utility of the use of an artificial intelligence (AI)-powered clinical decision aid tool in shared decision making between the cancer survivor patient and the cardiologist regarding prevention of cardiovascular disease. Design: This is a single-center, double-arm, open-label, randomized interventional feasibility study. Our cardio-oncology cohort of > 4000 individuals from our Clinical Research Data Warehouse will be queried to identify at least 200 adult cancer survivors who meet the eligibility criteria. Study participants will be randomized into either the Clinical Decision Aid Group (where patients will use the clinical decision aid in addition to current practice) or the Control Group (current practice). The primary endpoint of this study is to assess for each patient encounter whether cardiovascular medications and imaging pursued were consistent with current medical society recommendations. Additionally, the perceptions of using the clinical decision tool will be evaluated based on patient and physician feedback through surveys and focus groups. Summary: This trial will determine whether a clinical decision aid tool improves cancer survivors’ medication use and imaging surveillance recommendations aligned with current medical guidelines. Trial registration: ClinicalTrials.Gov Identifier: NCT05377320.
AB - Background: The many improvements in cancer therapies have led to an increased number of survivors, which comes with a greater risk of consequent/subsequent cardiovascular disease. Identifying effective management strategies that can mitigate this risk of cardiovascular complications is vital. Therefore, developing computer-driven and personalized clinical decision aid interventions that can provide early detection of patients at risk, stratify that risk, and recommend specific cardio-oncology management guidelines and expert consensus recommendations is critically important. Objectives: To assess the feasibility, acceptability, and utility of the use of an artificial intelligence (AI)-powered clinical decision aid tool in shared decision making between the cancer survivor patient and the cardiologist regarding prevention of cardiovascular disease. Design: This is a single-center, double-arm, open-label, randomized interventional feasibility study. Our cardio-oncology cohort of > 4000 individuals from our Clinical Research Data Warehouse will be queried to identify at least 200 adult cancer survivors who meet the eligibility criteria. Study participants will be randomized into either the Clinical Decision Aid Group (where patients will use the clinical decision aid in addition to current practice) or the Control Group (current practice). The primary endpoint of this study is to assess for each patient encounter whether cardiovascular medications and imaging pursued were consistent with current medical society recommendations. Additionally, the perceptions of using the clinical decision tool will be evaluated based on patient and physician feedback through surveys and focus groups. Summary: This trial will determine whether a clinical decision aid tool improves cancer survivors’ medication use and imaging surveillance recommendations aligned with current medical guidelines. Trial registration: ClinicalTrials.Gov Identifier: NCT05377320.
KW - Artificial intelligence
KW - Cancer survivors
KW - Cardio-oncology
KW - Cardiotoxicity
KW - Clinical decision aid
KW - Clinical decision support
KW - Machine learning
UR - http://www.scopus.com/inward/record.url?scp=85146885458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146885458&partnerID=8YFLogxK
U2 - 10.1186/s40959-022-00151-0
DO - 10.1186/s40959-022-00151-0
M3 - Article
AN - SCOPUS:85146885458
SN - 2057-3804
VL - 9
JO - Cardio-Oncology
JF - Cardio-Oncology
IS - 1
M1 - 7
ER -